National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Sildenafil (Revatio®)

Sildenafil (Revatio®) is indicated for:


Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity.

Paediatric population

Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension.

Rapid Review

Commenced Completed Outcome
16/04/2014 23/05/2014 Full Pharmacoeconomic Evaluation Not Recommended.